Atea Pharmaceuticals, Inc. (AVIR)
5.145
-0.01
(-0.19%)
USD |
NASDAQ |
Oct 09, 16:00
5.145
0.00 (0.00%)
After-Hours: 20:00
Atea Pharmaceuticals Enterprise Value : 194.41M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 194.41M |
| October 07, 2026 | 182.78M |
| October 06, 2026 | 187.60M |
| October 05, 2026 | 192.41M |
| October 02, 2026 | 192.41M |
| October 01, 2026 | 190.00M |
| September 30, 2026 | 198.83M |
| September 29, 2026 | 196.42M |
| September 28, 2026 | 198.02M |
| September 25, 2026 | 195.62M |
| September 24, 2026 | 195.62M |
| September 23, 2026 | 204.44M |
| September 22, 2026 | 233.31M |
| September 21, 2026 | 216.47M |
| September 18, 2026 | 208.45M |
| September 17, 2026 | 202.84M |
| September 16, 2026 | 194.01M |
| September 15, 2026 | 200.43M |
| September 14, 2026 | 207.65M |
| September 11, 2026 | 206.85M |
| September 10, 2026 | 196.42M |
| September 09, 2026 | 203.64M |
| September 08, 2026 | 236.52M |
| September 04, 2026 | 248.55M |
| September 03, 2026 | 247.75M |
| Date | Value |
|---|---|
| September 02, 2026 | 238.13M |
| September 01, 2026 | 221.28M |
| August 31, 2026 | 210.05M |
| August 28, 2026 | 210.86M |
| August 27, 2026 | 218.07M |
| August 26, 2026 | 222.89M |
| August 25, 2026 | 216.47M |
| August 24, 2026 | 222.89M |
| August 21, 2026 | 216.47M |
| August 20, 2026 | 210.86M |
| August 19, 2026 | 229.30M |
| August 18, 2026 | 204.44M |
| August 17, 2026 | 199.63M |
| August 14, 2026 | 191.61M |
| August 13, 2026 | 187.60M |
| August 12, 2026 | 186.79M |
| August 11, 2026 | 185.99M |
| August 10, 2026 | 183.59M |
| August 07, 2026 | 202.03M |
| August 06, 2026 | 181.18M |
| August 05, 2026 | 161.93M |
| August 04, 2026 | 157.92M |
| August 03, 2026 | 150.70M |
| July 31, 2026 | 157.92M |
| July 30, 2026 | 161.13M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -43.38M |
| CorMedix, Inc. | 456.32M |
| Eloxx Pharmaceuticals, Inc. | -0.6934M |
| Breakthrough Chemistry, Inc. | 0.2897M |
| BioStem Technologies, Inc. | 41.31M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -32.93M |
| Total Expenses (Quarterly) | 32.93M |
| EPS Diluted (Quarterly) | -0.4114 |
| Earnings Yield | -40.65% |
| Normalized Earnings Yield | -40.65 |